Published in Proc Natl Acad Sci U S A on May 01, 1993
DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A (1993) 4.49
DNA vaccines: ready for prime time? Nat Rev Genet (2008) 4.10
Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol (1998) 2.82
Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med (1997) 2.81
Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci U S A (1994) 2.58
Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci U S A (1994) 2.58
Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol (2011) 2.25
Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci U S A (1997) 2.20
Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol (1996) 2.15
Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J Virol (2001) 2.12
Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. Proc Natl Acad Sci U S A (1996) 2.02
Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci U S A (1996) 2.01
CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J Clin Invest (1998) 1.87
Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J Virol (1996) 1.80
Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol (2005) 1.78
Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol (1996) 1.71
Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials. Nat Rev Immunol (2009) 1.68
DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc Natl Acad Sci U S A (1995) 1.60
Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine (2008) 1.51
Retracted Prophylactic DNA vaccine for hepatitis C virus (HCV) infection: HCV-specific cytotoxic T lymphocyte induction and protection from HCV-recombinant vaccinia infection in an HLA-A2.1 transgenic mouse model. Proc Natl Acad Sci U S A (2000) 1.51
Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc Natl Acad Sci U S A (2000) 1.50
DNA immunization with Japanese encephalitis virus nonstructural protein NS1 elicits protective immunity in mice. J Virol (1998) 1.49
Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine (2008) 1.43
Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses. J Virol (1999) 1.43
Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. J Virol (2004) 1.40
Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. J Virol (1998) 1.39
Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J Virol (1997) 1.36
DNA vaccination against persistent viral infection. J Virol (1995) 1.33
Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther (2003) 1.28
Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice. J Virol (1995) 1.25
Induction of protective immunity against Japanese encephalitis in mice by immunization with a plasmid encoding Japanese encephalitis virus premembrane and envelope genes. J Virol (1998) 1.23
Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1. Proc Natl Acad Sci U S A (1997) 1.23
In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. J Virol (1999) 1.23
Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus. Proc Natl Acad Sci U S A (1995) 1.21
The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine (2008) 1.20
Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol (2013) 1.19
Cross-protection among lethal H5N2 influenza viruses induced by DNA vaccine to the hemagglutinin. J Virol (1997) 1.12
Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo. Curr Opin Virol (2011) 1.12
DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol (2010) 1.12
Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. Eur J Immunol (2003) 1.12
Induction of neonatal tolerance by plasmid DNA vaccination of mice. J Clin Invest (1996) 1.08
Immune responses to plasmid DNA encoding the hepatitis C virus core protein. J Virol (1995) 1.08
DNA vaccines for emerging infectious diseases: what if? Emerg Infect Dis (1996) 1.07
DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev (2004) 1.06
DNA-based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid. J Virol (1995) 1.03
Combination DNA plus protein HIV vaccines. Springer Semin Immunopathol (2006) 1.02
Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention. CNS Neurol Disord Drug Targets (2010) 1.02
Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines. Viruses (2009) 1.01
Assembly of erodible, DNA-containing thin films on the surfaces of polymer microparticles: toward a layer-by-layer approach to the delivery of DNA to antigen-presenting cells. Acta Biomater (2008) 1.01
Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. Proc Natl Acad Sci U S A (1996) 1.01
Increase of skeletal muscle relaxation speed by direct injection of parvalbumin cDNA. Proc Natl Acad Sci U S A (1995) 1.00
Genetic vaccination against malaria infection by intradermal and epidermal injections of a plasmid containing the gene encoding the Plasmodium berghei circumsporozoite protein. Infect Immun (2000) 1.00
Plasmid DNA encoding replicating foot-and-mouth disease virus genomes induces antiviral immune responses in swine. J Virol (1997) 1.00
Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope. J Virol (1997) 0.97
Bicistronic woodchuck hepatitis virus core and gamma interferon DNA vaccine can protect from hepatitis but does not elicit sterilizing antiviral immunity. J Virol (2006) 0.96
Immune response in mice following immunization with DNA encoding fragment C of tetanus toxin. Infect Immun (1996) 0.95
Refinement of a DNA based Alzheimer's disease epitope vaccine in rabbits. Hum Vaccin Immunother (2013) 0.94
Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors. J Virol (2001) 0.93
DNA vaccines for targeting bacterial infections. Expert Rev Vaccines (2010) 0.92
Synthetic DNA vaccine strategies against persistent viral infections. Expert Rev Vaccines (2013) 0.92
Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects. J Infect Dis (2011) 0.92
Safety and tolerability of the Easy Vax™ clinical epidermal electroporation system in healthy adults. Mol Ther (2011) 0.92
DNA-based vaccination induces humoral and cellular immune responses against hepatitis B virus surface antigen in mice without activation of C-myc. World J Gastroenterol (2000) 0.92
Targeted salivary gland immunization with plasmid DNA elicits specific salivary immunoglobulin A and G antibodies and serum immunoglobulin G antibodies in mice. Infect Immun (1999) 0.92
Macrophage inflammatory protein-1alpha (MIP-1alpha) expression plasmid enhances DNA vaccine-induced immune response against HIV-1. Clin Exp Immunol (1999) 0.91
Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins. J Virol (1994) 0.91
Replication of hepatitis delta virus RNA in mice after intramuscular injection of plasmid DNA. J Virol (1995) 0.90
Optimization of electroporation-enhanced intradermal delivery of DNA vaccine using a minimally invasive surface device. Hum Gene Ther Methods (2012) 0.90
Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy. CNS Neurol Disord Drug Targets (2009) 0.89
Prospects for control of emerging infectious diseases with plasmid DNA vaccines. J Immune Based Ther Vaccines (2009) 0.89
Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutralizing properties following DNA immunization. J Virol (1999) 0.89
DNA vaccines, electroporation and their applications in cancer treatment. Hum Vaccin Immunother (2015) 0.89
In vivo expression of a single viral DNA-binding protein generates systemic lupus erythematosus-related autoimmunity to double-stranded DNA and histones. Proc Natl Acad Sci U S A (1995) 0.88
Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection mode. J Virol (1997) 0.87
DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother (2014) 0.87
Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvants. J Virol (2000) 0.86
Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. J Virol (1997) 0.86
The next wave of recombinant and synthetic anticancer vaccines. Semin Cancer Biol (1995) 0.85
Engineering superior DNA vaccines: MHC class I single chain trimers bypass antigen processing and enhance the immune response to low affinity antigens. Vaccine (2010) 0.85
Intradermal DNA vaccination enhanced by low-current electroporation improves antigen expression and induces robust cellular and humoral immune responses. Hum Gene Ther (2012) 0.85
Infectivity of chimeric human T-cell leukemia virus type I molecular clones assessed by naked DNA inoculation. Proc Natl Acad Sci U S A (1996) 0.83
HIV-1-specific cell-mediated immunity is enhanced by co-inoculation of TCA3 expression plasmid with DNA vaccine. Immunology (1997) 0.83
Nucleic acid vaccines. Clin Microbiol Rev (1995) 0.83
Potentiation of antigen-specific, Th1 immune responses by multiple DNA vaccination with an ovalbumin/interferon-gamma hybrid construct. Immunology (1998) 0.82
In vivo role of B lymphocytes in somatic transgene immunization. Proc Natl Acad Sci U S A (1997) 0.82
Vaccines to prevent chronic hepatitis C virus infection: current experimental and preclinical developments. J Gastroenterol (2007) 0.81
Evaluation on the efficacy and immunogenicity of recombinant DNA plasmids expressing spike genes from porcine transmissible gastroenteritis virus and porcine epidemic diarrhea virus. PLoS One (2013) 0.80
Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1). BioDrugs (2009) 0.80
Enhanced nasal mucosal delivery and immunogenicity of anti-caries DNA vaccine through incorporation of anionic liposomes in chitosan/DNA complexes. PLoS One (2013) 0.80
Increasing a robust antigen-specific cytotoxic T lymphocyte response by FMDV DNA vaccination with IL-9 expressing construct. J Biomed Biotechnol (2010) 0.79
Immunization of mice with the nef gene from Human Immunodeficiency Virus type 1: study of immunological memory and long-term toxicology. Infect Agent Cancer (2007) 0.78
Boosting immune response to hepatitis B DNA vaccine by coadministration of Prothymosin alpha-expressing plasmid. Clin Diagn Lab Immunol (2005) 0.78
Amiloride enhances antigen specific CTL by faciliting HBV DNA vaccine entry into cells. PLoS One (2012) 0.77
Ultrasonic synthetic technique to manufacture a pHEMA nanopolymeric-based vaccine against the H6N2 avian influenza virus: a preliminary investigation. Int J Nanomedicine (2011) 0.77
Zymosan enhances the immune response to DNA vaccine for human immunodeficiency virus type-1 through the activation of complement system. Immunology (2001) 0.76
Intranasal immunization with plasmid DNA encoding spike protein of SARS-coronavirus/polyethylenimine nanoparticles elicits antigen-specific humoral and cellular immune responses. BMC Immunol (2010) 0.76
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature (1985) 30.47
T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature (1985) 21.57
Direct gene transfer into mouse muscle in vivo. Science (1990) 10.39
A molecular clone of HTLV-III with biological activity. Nature (1985) 8.30
Genetic immunization is a simple method for eliciting an immune response. Nature (1992) 5.30
Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay. J Clin Microbiol (1988) 4.25
Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs. Nature (1991) 3.03
Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science (1992) 2.83
Cytotoxic T-cell recognition of HIV proteins and peptides. AIDS (1991) 2.83
Site-specific gene expression in vivo by direct gene transfer into the arterial wall. Science (1990) 2.63
Vaccine protection of rhesus macaques against simian immunodeficiency virus infection. AIDS Res Hum Retroviruses (1990) 1.56
Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein. Oncogene (1989) 1.34
HIV-1 gp41 contains two sites for interaction with several proteins on the helper T-lymphoid cell line, H9. AIDS (1992) 1.29
Efficacy of SIV/deltaB670 glycoprotein-enriched and glycoprotein-depleted subunit vaccines in protecting against infection and disease in rhesus monkeys. AIDS (1991) 1.23
Passive immunization for the prevention and treatment of HIV infection. AIDS (1992) 1.08
Development of biologically active peptides based on antibody structure. Proc Natl Acad Sci U S A (1989) 1.03
CD3-associated heterodimeric polypeptides on suppressor hybridomas define biologically active inhibitory cells. Proc Natl Acad Sci U S A (1988) 1.00
Stable incorporation of a bacterial gene into adult rat skeletal muscle in vivo. Am J Physiol (1990) 0.94
The intersection of online social networking with medical professionalism. J Gen Intern Med (2008) 7.79
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35
THE STANDARDIZATION OF ANTIPNEUMOCOCCIC SERUM TYPES I AND II. J Exp Med (1930) 5.18
c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature (2001) 4.46
Retracted Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity (1999) 4.42
First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis (1998) 3.60
Complete DNA sequence of yeast chromosome XI. Nature (1994) 3.51
Predictions and measurements of scattering and absorption over broad wavelength ranges in tissue phantoms. Appl Opt (1997) 3.40
A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature (1989) 3.27
Induction of cell differentiation by human immunodeficiency virus 1 vpr. Cell (1993) 2.90
HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B. Nat Med (1997) 2.56
Alcohol and injury. A case-crossover study. Arch Fam Med (1995) 2.49
Effects of Cations and Abscisic Acid on Chlorophyll a Fluorescence in Guard Cells of Vicia faba. Plant Physiol (1982) 2.38
Patients with an ultrasonographic cervical length < or =15 mm have nearly a 50% risk of early spontaneous preterm delivery. Am J Obstet Gynecol (2000) 2.21
Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat Med (1997) 2.12
Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1994) 2.00
Cleavage of yeast and bacteriophage T7 genomes at a single site using the rare cutter endonuclease I-Sce I. Nucleic Acids Res (1991) 1.96
CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J Clin Invest (1998) 1.87
Cyanoacrylate glue in gastric variceal bleeding. Endoscopy (2002) 1.86
Retracted Autoimmunity as a consequence of retrovirus-mediated expression of C-FLIP in lymphocytes. Immunity (1999) 1.78
p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res (1990) 1.75
Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency. J Virol (1995) 1.74
Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem (2000) 1.68
Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr. J Virol (1997) 1.65
Induction of potent Th1-type immune responses from a novel DNA vaccine for West Nile virus New York isolate (WNV-NY1999). J Infect Dis (2001) 1.61
Peptide mimicry of carbohydrate epitopes on human immunodeficiency virus. Nat Biotechnol (1997) 1.61
DNA vaccination: antigen presentation and the induction of immunity. J Leukoc Biol (2000) 1.60
Spectroscopic diagnosis of bladder cancer with elastic light scattering. Lasers Surg Med (1995) 1.60
Multicentre prospective controlled study of Barrett's oesophagus and colorectal adenomas. Groupe d'Etude de l'Oesophage de Barrett. Lancet (1995) 1.59
Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines. J Infect Dis (2000) 1.59
PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer. Cancer Res (2000) 1.57
Molecular detection of bacterial DNA in venereal-associated arthritis. Arthritis Rheum (1996) 1.55
Pancreas divisum and pancreatitis: a coincidental association? Endoscopy (1991) 1.55
In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol (1997) 1.53
The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product. Proc Natl Acad Sci U S A (1995) 1.53
Prevention in mental health: a controlled study. Am J Psychiatry (1975) 1.52
What role can endoscopy play in the management of biliary complications after laparoscopic cholecystectomy? Endoscopy (1997) 1.52
Endoscopic sphincterotomy prior to laparoscopic cholecystectomy for the treatment of cholelithiasis. Surg Endosc (2003) 1.51
IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge. J Immunol (1999) 1.48
Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes. Nat Biotechnol (1997) 1.47
Inducible chromosomal translocation of AML1 and ETO genes through Cre/loxP-mediated recombination in the mouse. EMBO Rep (2000) 1.44
Influence of sex, age and smoking status on patient comfort during gastroscopy with pharyngeal anesthesia by a new benzocaine-tetracaine preparation. Can J Gastroenterol (1998) 1.42
Hyperglycemia and hyperosmolality complicating peritoneal dialysis. Ann Intern Med (1967) 1.40
Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis. J Pharmacol Exp Ther (2002) 1.40
Abortion. Can Med Assoc J (1974) 1.38
Inflammatory changes parallel the early stages of Alzheimer disease. Neurobiol Aging (2006) 1.37
Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device. Gene Ther (2010) 1.35
Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein. Oncogene (1989) 1.34
Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur J Immunol (1998) 1.30
Targeted antigen delivery to antigen-presenting cells including dendritic cells by engineered Fas-mediated apoptosis. Nat Biotechnol (2000) 1.29
In vivo protective anti-HIV immune responses in non-human primates through DNA immunization. J Med Primatol (1996) 1.29
Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. Cancer Res (1990) 1.26
ANX7, a candidate tumor suppressor gene for prostate cancer. Proc Natl Acad Sci U S A (2001) 1.26
Endoscopic ultrasonographic signs of portal hypertension in cirrhosis. Gastrointest Endosc (1996) 1.25
DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and nonhuman primates. DNA Cell Biol (1993) 1.25
ATP transduces signals from ASGM1, a glycolipid that functions as a bacterial receptor. Proc Natl Acad Sci U S A (2001) 1.25
Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells. J Immunol (1998) 1.25
DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4(+) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo. J Virol (2000) 1.23
Late recurrence of a hepatic angiomyolipoma. Eur J Gastroenterol Hepatol (2000) 1.23
Sequences of the cell-attachment sites of reovirus type 3 and its anti-idiotypic/antireceptor antibody: modeling of their three-dimensional structures. Proc Natl Acad Sci U S A (1988) 1.23
In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. J Virol (1999) 1.23
Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer. J Urol (2000) 1.22
Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. Gastroenterology (1997) 1.22
Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1. J Clin Invest (1992) 1.20
Homelessness from a health visitor's viewpoint. Health Visit (1986) 1.19
Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol (2001) 1.19
Pharmacological and second messenger signalling selectivities of cloned P2Y receptors. J Auton Pharmacol (1996) 1.18
Argon plasma coagulation for the treatment of hemorrhagic radiation proctitis. Endoscopy (2000) 1.17
Construction of a recombinant bacterial human CD4 expression system producing a bioactive CD4 molecule. Viral Immunol (1992) 1.16
Restricted heterogeneity of T cell receptor transcripts in rheumatoid synovium. J Clin Invest (1992) 1.15
Antral motility in patients with cirrhosis with or without gastric antral vascular ectasia. Gut (1995) 1.14
The real Doctor Guillotin. JAMA (1972) 1.14
HIV-1 Vpr interacts with a human 34-kDa mov34 homologue, a cellular factor linked to the G2/M phase transition of the mammalian cell cycle. Proc Natl Acad Sci U S A (1998) 1.14
Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products. Proc Natl Acad Sci U S A (1988) 1.14